Literature DB >> 2865151

CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action.

W P Koella.   

Abstract

beta-Adrenoreceptor antagonists are liable to produce behavioural side-effects such as drowsiness, fatigue, lethargy, sleep disorders, nightmares, depressive moods, and hallucinations. These undesirable actions indicate that beta-blockers affect not only peripheral autonomic activity but also some central nervous mechanisms. In experimental animals beta-blockers have been found to reduce spontaneous motor activity, to counteract isolation-, lesion-, stimulation- and amphetamine-induced hyperactivity, and to produce slow-wave and paradoxical sleep disturbances. Furthermore, central effects such as tranquilizing influences are used for the treatment of conditions such as anxiety. Several different mechanisms of action could be responsible for these CNS effects: Centrally mediated specific actions on centrally located beta-adrenergic receptors, known to exist downstream from, and at the terminals of, 'vigilance-enhancing' central noradrenergic pathways. Centrally mediated specific actions on centrally located receptors of the non-adrenergic type; an affinity of some beta-blockers towards 5-HT-receptors is well documented. Centrally mediated non-specific actions on centrally located neurones, owing to the membrane-stabilizing effects of beta-blockers. Peripherally mediated actions whereby beta-blockers induce changes in the autonomic activity in the periphery, which are relayed to the CNS to induce changes in activity of a variety of central systems. It can be assumed that with any one of the beta-blockers all these mechanisms come into play, yet with varying degrees depending on characteristics of the drugs such as lipophilicity and hydrophilicity, the ratio of antagonist versus (partial) agonist properties, affinity to 'alien' receptor sites, strength of membrane-stabilizing activity, stereospecific affinity, and potency.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2865151     DOI: 10.1007/bf00543711

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  63 in total

1.  Direct evidence for an interaction of beta-adrenergic blockers with the 5-HT receptor.

Authors: 
Journal:  Nature       Date:  1977-05-19       Impact factor: 49.962

2.  Dual adreoceptor-mediated control of noradrenaline secretion from human vasoconstrictor nerves: facilitation by BETA-receptors and inhibitor by alpha-receptors.

Authors:  L Stj-5aarne; J Brundin
Journal:  Acta Physiol Scand       Date:  1975-05

Review 3.  On the psychopharmacology of beta adrenergic blockade.

Authors:  D J Greenblatt; R I Shader
Journal:  Curr Ther Res Clin Exp       Date:  1972-09

4.  Modification by two beta-adrenergic blocking drugs of the effects of methamphetamine on behaviour and brain metabolism of mice.

Authors:  C J Estler; H P Ammon
Journal:  J Neurochem       Date:  1971-05       Impact factor: 5.372

5.  Effect of propranolol on active users of heroin.

Authors:  H J Grosz
Journal:  Lancet       Date:  1973-09-15       Impact factor: 79.321

6.  Intrahypothalamic and intrastriatal dopamine and norepinephrine injections in relation to motor hyperactivity in rats.

Authors:  O Benkert; B Köhler
Journal:  Psychopharmacologia       Date:  1972

7.  Effects of systemic administration of propranolol on the timing behavior (DRL-20) of rats.

Authors:  J S Richardson; P D Stacey; N J Russo; R E Musty
Journal:  Arch Int Pharmacodyn Ther       Date:  1972-05

Review 8.  Central actions of beta-adrenoceptor blocking drugs in man.

Authors:  L Patel; P Turner
Journal:  Med Res Rev       Date:  1981       Impact factor: 12.944

Review 9.  Beta-adrenoceptor antagonists in psychiatry and neurology.

Authors:  D N Middlemiss; D A Buxton; D T Greenwood
Journal:  Pharmacol Ther       Date:  1981       Impact factor: 12.310

10.  Use of beta-blocking drugs in psychiatry and neurology.

Authors:  P J Tyrer
Journal:  Drugs       Date:  1980-10       Impact factor: 9.546

View more
  19 in total

Review 1.  Central mechanism of action of antimigraine prophylactic drugs.

Authors:  Gerardo Casucci; Veronica Villani; Fabio Frediani
Journal:  Neurol Sci       Date:  2008-05       Impact factor: 3.307

2.  Subjective symptoms and pharmacokinetics/dynamics of metoprolol CR in elderly subjects--a comparison with atenolol.

Authors:  E S Dimenäs; C G Dahlöf; B Heibel; R G Moore; B K Olofsson; G E Westergren; P W Lücker
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  A randomized trial of propranolol versus sodium valproate for the prophylaxis of migraine in pediatric patients.

Authors:  Elham Bidabadi; Mehryar Mashouf
Journal:  Paediatr Drugs       Date:  2010-08-01       Impact factor: 3.022

4.  (R,R')-4'-methoxy-1-naphthylfenoterol targets GPR55-mediated ligand internalization and impairs cancer cell motility.

Authors:  Rajib K Paul; Artur Wnorowski; Isabel Gonzalez-Mariscal; Surendra K Nayak; Karolina Pajak; Ruin Moaddel; Fred E Indig; Michel Bernier; Irving W Wainer
Journal:  Biochem Pharmacol       Date:  2013-12-16       Impact factor: 5.858

Review 5.  Prophylactic Treatment of Migraine.

Authors:  Azize Esra Gürsoy; Mustafa Ertaş
Journal:  Noro Psikiyatr Ars       Date:  2013-08-01       Impact factor: 1.339

6.  Prediction of sleep disorders induced by beta-adrenergic receptor blocking agents based on receptor occupancy.

Authors:  Y Yamada; F Shibuya; J Hamada; Y Sawada; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1995-04

Review 7.  Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action.

Authors:  Till Sprenger; M Viana; C Tassorelli
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

8.  CNS side effects of centrally-active antihypertensive agents: a prospective, placebo-controlled study of sleep, mood state, and cognitive and sexual function in hypertensive males.

Authors:  J B Kostis; R C Rosen; B C Holzer; C Randolph; L S Taska; M H Miller
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

9.  Changes in depressive status associated with topical beta-blockers.

Authors:  S Duch; C Duch; L Pastó; P Ferrer
Journal:  Int Ophthalmol       Date:  1992-09       Impact factor: 2.031

10.  Patient outcome in migraine prophylaxis: the role of psychopharmacological agents.

Authors:  Maurizio Pompili; Gianluca Serafini; Marco Innamorati; Giulia Serra; Giovanni Dominici; Juliana Fortes-Lindau; Monica Pastina; Ludovica Telesforo; David Lester; Paolo Girardi; Roberto Tatarelli; Paolo Martelletti
Journal:  Patient Relat Outcome Meas       Date:  2010-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.